✦ LIBER ✦

Interleukin-6 receptor inhibition with tocilizumab and attainment of disease remission in rheumatoid arthritis: The role of acute-phase reactants

✍ Scribed by Josef S. Smolen; Daniel Aletaha

Publisher: John Wiley and Sons
Year: 2010
Tongue: English
Weight: 401 KB
Volume: 63
Category: Article
ISSN: 0004-3591
DOI: 10.1002/art.27740

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Interleukin-6 receptor inhibition with t

Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: The tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study

✍ Mark C. Genovese; James D. McKay; Evgeny L. Nasonov; Eduardo F. Mysler; Nilzio A 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 148 KB 👁 2 views

Double-blind randomized controlled clini

Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate

✍ R. N. Maini; P. C. Taylor; J. Szechinski; K. Pavelka; J. Bröll; G. Balint; P. Em 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 320 KB 👁 2 views

Rapid and sustained improvement in bone

Rapid and sustained improvement in bone and cartilage turnover markers with the anti–interleukin-6 receptor inhibitor tocilizumab plus methotrexate in rheumatoid arthritis patients with an inadequate response to methotrexate: Results from a substudy of the multicenter double-blind, placebo-controlled trial of tocilizumab in inadequate responders to methotrexate alone

✍ Patrick Garnero; Elizabeth Thompson; Thasia Woodworth; Josef S. Smolen 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 276 KB 👁 2 views

## Abstract ## Objective To investigate the effects of tocilizumab (TCZ) added to a stable dosage of methotrexate (MTX) on biochemical markers of bone and cartilage metabolism in patients in the multicenter double‐blind, placebo‐controlled OPTION (Tocilizumab Pivotal Trial in Methotrexate Inadequa